The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
Quell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.
Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.
The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Pfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
The EU has secured 60 million doses of Valnevas potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.